Boston Scientific Could Cut Its 2026 Outlook for a Third Time. Is BSX Stock Finally Cheap?

Mikirduit — Boston Scientific Corp. (NYSE: BSX) is warning investors that it is unlikely to meet its third-quarter and full-year 2026 financial targets after a cybersecurity incident disrupted manufacturing and distribution across its global operations.

3 Key Takeaways

• Boston Scientific’s cyberattack is likely to hurt third-quarter results, but the bigger concern is that growth was already slowing before the disruption.
• BSX now trades at a steep discount to its historical valuation and several medtech peers after the stock fell more than 50%.
• The Oct. 28 earnings report will be crucial because investors need to see how much revenue was delayed, how quickly backlog is recovered and how far management resets 2026 guidance.

The latest setback raises the prospect of a third reduction to Boston Scientific's 2026 outlook when the medical-device maker reports third-quarter results on Oct. 28.

For investors, however, the cyberattack isn't the only issue.

Boston Scientific's growth was already slowing before the incident, particularly in businesses such as WATCHMAN, electrophysiology and cardiac rhythm management. That makes the central question more complicated: Is the roughly 50% decline in BSX shares creating an opportunity—or is the lower valuation simply reflecting weaker growth?

The Cyberattack Disrupted Boston Scientific's Global Operations

Boston Scientific identified unauthorized activity in certain information-technology systems on Aug. 25, 2026.

The incident caused a network outage that restricted access to operating systems and business applications, affecting the company's ability to manufacture products as well as process and ship customer orders.

By its Sept. 8 regulatory filing, Boston Scientific said it had found no evidence of ongoing unauthorized access, although its investigation remained underway.

Operations have improved considerably.

The company said its distribution network had been substantially restored, with major distribution centers processing and shipping orders at or above normal operating levels. Sterilization facilities were operational again, while manufacturing had resumed across most of its global facilities.

Boston Scientific is now working through the backlog created during the disruption.

Still, management concluded that the incident is likely to have a material impact on third-quarter and full-year 2026 results and said it is unlikely to meet the sales-growth and adjusted-EPS targets it issued in July.

The company plans to provide an updated outlook with its third-quarter earnings release on Oct. 28.

Oil Is Closing In on $100 a Barrel. Here’s What Investors Can Do Now

Oil prices are closing in on $100 a barrel as Middle East tensions and tighter supply lift crude, creating upside for energy stocks but raising fresh inflation and Fed risks.

Mikirduit USSurya Rianto

How Much Revenue Could Have Been Delayed?

The financial impact remains uncertain, but the size of Boston Scientific's business offers some indication of the potential exposure.

The company generated $5.44 billion in second-quarter revenue, or roughly $419 million a week on a simple quarterly average.

If production and shipments were impaired for roughly two weeks, and activity during that period fell anywhere from 20% to 50%, a rough calculation suggests that $170 million to $420 million of revenue could have been delayed.

That isn't an official estimate from Boston Scientific.

And delayed revenue isn't necessarily lost revenue.

Because the company is working through its order backlog as distribution and production recover, some sales that weren't recognized during the disruption could simply shift from the third quarter into a later period.

The more significant short-term problem could be margins.

Factories running below normal capacity, disrupted logistics and recovery expenses can weigh on profitability even if much of the delayed revenue is eventually recovered.

Before the cyberattack, Boston Scientific expected third-quarter reported sales growth of 3% to 5% and adjusted earnings of $0.80 to $0.82 a share.

A miss is now likely.

The severity of that miss—and the size of the subsequent guidance reset—could determine the stock's next major move.

Boston Scientific Was Already Cutting Its Forecast Before the Attack

The cyberattack matters, but investors shouldn't mistake it for the sole reason Boston Scientific's outlook has deteriorated.

Management had already lowered its 2026 forecast twice.

At the beginning of February, Boston Scientific projected full-year reported sales growth of 10.5% to 11.5% and adjusted EPS of $3.43 to $3.49.

Following first-quarter results in April, the company lowered the ranges to:

• 7% to 8.5% reported sales growth
• $3.34 to $3.41 adjusted EPS

Then in July, after reporting its second-quarter results, Boston Scientific reduced its outlook again to:

• 5.5% to 6.5% reported sales growth
• $3.28 to $3.32 adjusted EPS

Now management says even those targets are unlikely to be achieved because of the cyberattack.

If Boston Scientific formally lowers its targets again in October, that would mark the third downward revision to its 2026 outlook.

That trajectory is important because it shows that BSX's fundamental slowdown predates the cybersecurity incident.

WATCHMAN Growth Is Losing Momentum

One source of pressure is Boston Scientific's WATCHMAN franchise.

WATCHMAN is a left atrial appendage closure device designed to reduce stroke risk in certain patients with non-valvular atrial fibrillation.

The underlying left atrial appendage closure, or LAAC, market has slowed.

New clinical data have changed the conversation between physicians and patients. In some cases, patients who might previously have been referred relatively quickly for an LAAC procedure are being monitored longer or treated with anticoagulant medications instead.

Boston Scientific's regulatory filings acknowledge a deceleration in certain WATCHMAN procedures during the first half of 2026.

WATCHMAN sales are still growing on a year-to-date basis—roughly 4.2% in our calculations—but the pace has clearly moderated.

That matters because the market previously assigned Boston Scientific a premium valuation partly on the expectation of sustained above-market growth from its cardiovascular franchises.

Slower WATCHMAN growth puts pressure on that assumption.

Farapulse Is Growing, but Competition Is Getting Tougher

The picture is different for Farapulse, Boston Scientific's pulsed-field ablation platform used in the treatment of atrial fibrillation.

Demand remains relatively healthy.

Boston Scientific said its electrophysiology business continued to benefit from the Farapulse system during the first half of 2026. At the same time, however, the company explicitly cited increased competition within electrophysiology as a headwind.

That distinction is crucial.

The problem isn't necessarily that the market for pulsed-field ablation has stopped growing.

The problem is that Boston Scientific no longer has the field largely to itself.

Competitors including Johnson & Johnson MedTech and Medtronic are fighting for a larger share of the rapidly developing electrophysiology market.

Based on our calculations, Boston Scientific's Farapulse-related electrophysiology business generated roughly 9.1% growth during the first half of 2026.

International growth remained particularly strong at about 23%, while growth in the U.S. was closer to 3%.

That divergence suggests Boston Scientific continues to have a meaningful growth asset in Farapulse, but competitive pressure in its most important domestic market deserves close attention.

Cardiac Rhythm Management Is Another Weak Spot

Boston Scientific's Cardiac Rhythm Management business has also faced pressure.

Our calculations indicate sales declined roughly 1.6%, with increased competition weighing on the segment.

Taken together, these trends provide a more complete explanation for the stock's weakness.

The cyberattack is a temporary operational shock.

But slowing WATCHMAN procedures, intensifying competition in electrophysiology and weakness in Cardiac Rhythm Management are fundamental issues that could influence growth well beyond the third quarter.

BSX Stock Has Already Fallen More Than 50%

The market has punished Boston Scientific severely.

Shares closed at $44.98 on Sept. 8, falling 5.9% on the day following the latest cybersecurity disclosure.

The stock was down roughly 53% year to date and about 58% over the previous 12 months.

That collapse has dramatically changed the valuation.

Boston Scientific is no longer trading like one of the market's premium medical-technology growth stocks.

Whether that makes the shares attractive depends on whether investors believe the growth deterioration is temporary.

Valuation: BSX Now Screens Cheap

We evaluated Boston Scientific against four large medical-technology peers:

• Abbott Laboratories (NYSE: ABT)
• Medtronic (NYSE: MDT)
• Stryker (NYSE: SYK)
• Johnson & Johnson (NYSE: JNJ)

We looked at three relative valuation measures—price-to-earnings, price-to-book and price-to-sales—as well as our discounted-cash-flow estimates.

Historical Valuation

Boston Scientific's current valuation is significantly below its own recent history.

BSX trades at roughly 17.7 times earnings, compared with an average five-year P/E multiple of approximately 55.8 times.

Its price-to-sales ratio has fallen to about 3.1 times, versus a five-year average of around 6.3 times.

Those discounts are substantial.

But they aren't entirely surprising.

The stock has lost more than half of its value while Boston Scientific's first-half 2026 net income still increased roughly 52% to $2.2 billion.

The market isn't questioning the profits already reported.

It is questioning the trajectory of future growth.

BSX Is Also Cheap Relative to Peers

Boston Scientific currently has the lowest P/E multiple among the peer group in our comparison.

Boston Scientific also trades at around 3.1 times sales, tying Medtronic for the lowest price-to-sales multiple in the group.

The other companies trade at approximately:

• Abbott: 4.7x
• Stryker: 4.1x
• Johnson & Johnson: 6.6x

On relative valuation alone, BSX is starting to look unusually inexpensive.

The bigger issue is whether the discount is large enough to compensate investors for the deteriorating earnings outlook.

Our DCF Suggests Meaningful Upside

Our discounted-cash-flow analysis produces a fair-value estimate of approximately $66.65 a share for Boston Scientific.

Against the Sept. 8 closing price of $44.98, that implies potential upside of roughly 48%.

Our DCF estimates for the peer group show a smaller upside in most cases:

• Abbott Laboratories: $114.82 fair value, about 8.8% upside
• Medtronic: $100.46 fair value, about 8.7% upside
• Stryker: $364.88 fair value, about 32% upside
• Johnson & Johnson: $254.36 fair value, about 5.5% downside

By this measure, Boston Scientific offers the largest theoretical upside in the group.

But DCF models are especially sensitive when a company's earnings expectations are being revised downward.

If Boston Scientific's post-cyberattack guidance implies structurally weaker revenue growth or lower margins than our model assumes, the fair-value estimate would need to come down as well.

The Bottom Line

Boston Scientific stock is unquestionably cheaper than it was.

That doesn't necessarily mean the stock has finished falling.

The cyberattack appears to be moving from the disruption phase into the recovery phase: major distribution centers are shipping again, sterilization facilities are operating, manufacturing has resumed across most sites and the company is working through its backlog.

That makes the cyber incident potentially temporary.

The harder questions concern the underlying business.

WATCHMAN growth has slowed. Competition around Farapulse is increasing. Cardiac Rhythm Management has weakened. And management had already lowered its full-year guidance twice before the cyberattack occurred.

That is why the Oct. 28 earnings report may matter more than the cyberattack itself.

Investors will need to watch three things: the size of the third-quarter revenue disruption, how much of the backlog Boston Scientific expects to recover, and—most importantly—where management resets its 2026 growth and earnings targets.

At $44.98, BSX appears inexpensive both relative to its own history and several major medical-device peers. Our DCF also points to substantial upside.

But the valuation discount comes with a catch.

If October's guidance reset is relatively modest and management shows that most cyber-related revenue was delayed rather than lost, the selloff could begin to look excessive.

If management delivers another major reduction in its growth outlook, however, the market could conclude that Boston Scientific's problem isn't merely a cyberattack.

It is a slower-growth business that still needs to find its new valuation.

The numbers are only the beginning.

Every week, Mikirduit US breaks down earnings, valuations, catalysts, and risks across U.S. stocks—so you can see what the market may be missing.

Get the Weekly Briefing